FDA Panel Backs Long-Acting Boehringer Inhaler

Chrome 2001
.
Aetna Intelihealth InteliHealth Aetna Intelihealth Aetna Intelihealth
 
.
. .
Harvard Medical School

   Advertisement
Carepass Ad Carepass Ad .
Chrome 2001
Chrome 2001
.

FDA Panel Backs Long-Acting Boehringer Inhaler

Women's Health
9103
Women's Health
FDA Panel Backs Long-Acting Boehringer Inhaler
FDA Panel Backs Long-Acting Boehringer Inhaler
apdigital_2013_01_29_ap.online.health-medical_DA443RDO1_news_ap_org.anpa
WASHINGTON (AP) -- A panel of federal health experts on Tuesday overwhelmingly recommended approval for a long-acting inhaler to treat people suffering from chronic lung disease.
1473255
InteliHealth
2013-01-30
t
Associated Press
2013-03-01
Associated Press
FDA Panel Backs Long-Acting Boehringer Inhaler
January 30, 2013

WASHINGTON (AP) -- A panel of federal health experts on Tuesday overwhelmingly recommended approval for a long-acting inhaler to treat people suffering from chronic lung disease.

The Food and Drug Administration panel voted 15-1, with one abstention, that Boehringer Ingelheim's once-daily Striverdi Respimat (STRIH-ver-dee Res-peh-mat) inhaler is safe and effective for chronic obstructive pulmonary disease, a condition that causes bronchitis and emphysema.

The disease affects about 24 million people in the U.S. and is most commonly caused by cigarette smoking. Symptoms include cough, phlegm and shortness of breath.

The FDA is not required to follow the guidance of its panels, though it often does.

German drugmaker Boehringer is also asking the agency to approve the drug, known chemically as olodaterol, with labeling stating that it increased patients' ability to exercise. If approved, the drug would be the first inhaler with that claim.

Boehringer studied the drug in patients for up to 48 weeks, measuring their lung capacity based on volume of air they could expel.

"The positive vote from the advisory committee marks an important step towards making olodaterol available," said Boehringer vice president Tunde Otulana in a statement.

Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

341, 342, 343, 8010, 8896, 21291, 888343,
drug
343
Last updated January 30, 2013


    Print Printer-friendly format    
   
.
.  
This website is certified by Health On the Net Foundation. Click to verify.
.